Cytomegalovirus reactivation in patients with multiple myeloma. Hasegawa T et al. Eur J Haematol. 2015 Mar 21. doi: 10.1111/ejh.12551. [Epub ahead of print] Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Gonsalves WI et al. Blood Cancer J. 2015 Mar 20;5:e296. doi: 10.1038/bcj.2015.20. Multiple myeloma presenting with a maxillary lesion as the first sign. Ramaiah KK et…
Iterative Decomposition of Water and Fat with Echo Asymmetry and Least-Squares Estimation (IDEAL) Magnetic Resonance Imaging as a Biomarker for Symptomatic Multiple Myeloma. Takasu M et al. PLoS One. 2015 Feb 23;10(2):e0116842. doi: 10.1371/journal.pone.0116842. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Vij R et al. Leuk Lymphoma. 2015 Feb 20:1-12. [Epub ahead…
OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Holtick U et al. Eur J Haematol. 2015 Feb 23. doi: 10.1111/ejh.12541. [Epub ahead of print]. Use of allogeneic platelet gel in the management of chemotherapy extravasation injuries: a case report. Di Costanzo G et al. Onco…
The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence. Hostenkamp G et al. Soc Sci Med. 2015 Feb 7;130C:162-171. doi: 10.1016/j.socscimed.2015.02.003. [Epub ahead of print]. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. Ashjian E et al. J Oncol Pharm Pract. 2015 Feb 17. pii: 1078155215572036. [Epub ahead of print]. Advance…
Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment. Wang L et al. Clin J Oncol Nurs. 2015 Feb 1;19(1):E4-7. doi: 10.1188/15.CJON.E4-E7. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Peng L et al. Support Care Cancer. 2015 Feb 13. [Epub ahead of print]. Renal insufficiency retains adverse prognostic implications despite renal function improvement following…
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Harrison SJ et al. Am J Hematol. 2015 Feb 4. doi: 10.1002/ajh.23967. [Epub ahead of print].
Plasmapheresis in cast nephropathy: yes or no? Madore F. Curr Opin Nephrol Hypertens. 2015 Jan 14. [Epub ahead of print]. Antimicrobial peptides: an alternative for innovative medicines? da Costa JP et al. Appl Microbiol Biotechnol. 2015 Jan 15. [Epub ahead of print]. Outcomes following surgical intervention for impending and gross instability caused by multiple myeloma in the spinal column. Zadnik PL et al. J…
Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Arroz M et al. Cytometry B Clin Cytom. 2015 Jan 23. doi: 10.1002/cyto.b.21228. [Epub ahead of print]. Novel agents have a significant impact on survival of patients with multiple myeloma. Lamm W et al. Wien Klin Wochenschr. 2015 Jan 22. [Epub ahead of print]. Multiple myeloma. Mehta A. Hematology. 2015 Jan;20(1):58-9. doi: 10.1179/1024533214Z.000000000333.…
Pleural effusion formation in the course of myeloma. Comert M etal. Arch Bronconeumol. 2015 Jan 22. pii: S0300-2896(14)00242-7. doi: 10.1016/j.arbres.2014.05.009. [Epub ahead of print]. Diagnosis of monoclonal gammopathy of renal significance. Bridoux F et al. Kidney Int. 2015 Jan 21. doi: 10.1038/ki.2014.408. [Epub ahead of print]. Paralytic ileus following “subcutaneous bortezomib” therapy: focus on the clinical emergency-report of two cases. Mele…
An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma. Nishihori T et al. Eur J Haematol. 2015 Jan 20. doi: 10.1111/ejh.12509. [Epub ahead of print]. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myelomanot eligible for or who deferred autologous stem cell transplantation.…